Zymeworks (ZYME) Competitors $17.23 +0.63 (+3.80%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. KRYS, PTCT, MENS, ARWR, ACLX, PCVX, CRNX, PTGX, KYMR, and MLTXShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors Krystal Biotech PTC Therapeutics Jyong Biotech Arrowhead Pharmaceuticals Arcellx Vaxcyte Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics MoonLake Immunotherapeutics Zymeworks (NASDAQ:ZYME) and Krystal Biotech (NASDAQ:KRYS) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation. Do analysts recommend ZYME or KRYS? Krystal Biotech has a consensus target price of $209.00, indicating a potential upside of 18.25%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the media refer more to ZYME or KRYS? In the previous week, Krystal Biotech had 2 more articles in the media than Zymeworks. MarketBeat recorded 2 mentions for Krystal Biotech and 0 mentions for Zymeworks. Krystal Biotech's average media sentiment score of 1.89 beat Zymeworks' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Overall Sentiment Zymeworks Neutral Krystal Biotech Very Positive Do institutionals and insiders believe in ZYME or KRYS? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by company insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, ZYME or KRYS? Zymeworks has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Is ZYME or KRYS more profitable? Krystal Biotech has a net margin of 40.85% compared to Zymeworks' net margin of -59.96%. Krystal Biotech's return on equity of 15.21% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-59.96% -21.59% -16.52% Krystal Biotech 40.85%15.21%13.81% Which has preferable earnings & valuation, ZYME or KRYS? Krystal Biotech has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$76.30M16.97-$122.69M-$0.97-17.76Krystal Biotech$290.52M17.61$89.16M$4.9235.92 SummaryKrystal Biotech beats Zymeworks on 14 of the 16 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$1.25B$942.72M$2.52B$10.38BDividend YieldN/A4.84%2.51%4.70%P/E Ratio-17.761.2326.6526.39Price / Sales16.97126.48249.15228.43Price / CashN/A17.6447.3130.68Price / Book3.506.6136.316.40Net Income-$122.69M-$5.42M$12.55M$276.69M7 Day Performance4.23%4.76%-0.51%-0.28%1 Month Performance16.34%3.36%3.11%6.69%1 Year PerformanceN/A27.29%71.95%27.61% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks0.0074 of 5 stars$17.23+3.8%N/AN/A$1.25B$76.30M-17.76460KRYSKrystal Biotech4.8961 of 5 stars$167.82+4.1%$209.00+24.5%-5.3%$4.86B$290.52M34.11210Positive NewsPTCTPTC Therapeutics3.8281 of 5 stars$58.99+2.0%$69.00+17.0%+57.1%$4.69B$806.78M8.461,410Positive NewsMENSJyong BiotechN/A$59.74+0.8%N/AN/A$4.54BN/A0.0031Gap DownHigh Trading VolumeARWRArrowhead Pharmaceuticals4.2655 of 5 stars$32.80+3.6%$43.14+31.5%+66.8%$4.53B$3.55M-25.63400Positive NewsACLXArcellx1.7482 of 5 stars$79.75+1.7%$114.31+43.3%-3.6%$4.42B$107.94M-23.3280Insider TradePCVXVaxcyte1.9163 of 5 stars$33.98+5.7%$106.25+212.7%-70.0%$4.41BN/A-8.27160Positive NewsCRNXCrinetics Pharmaceuticals3.9076 of 5 stars$45.91+27.9%$70.88+54.4%-9.5%$4.32B$1.04M-11.17210Trending NewsAnalyst ForecastOptions VolumeHigh Trading VolumePTGXProtagonist Therapeutics1.6325 of 5 stars$67.42+4.2%$68.36+1.4%+51.3%$4.19B$434.43M96.32120KYMRKymera Therapeutics1.0513 of 5 stars$56.25+4.7%$59.95+6.6%+15.5%$4.02B$47.07M-16.21170MLTXMoonLake Immunotherapeutics2.8602 of 5 stars$61.99+10.0%$74.43+20.1%+25.5%$3.98BN/A-22.302Trending NewsAnalyst DowngradeOptions VolumeGap DownHigh Trading Volume Related Companies and Tools Related Companies Krystal Biotech Alternatives PTC Therapeutics Alternatives Jyong Biotech Alternatives Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Vaxcyte Alternatives Crinetics Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Kymera Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYME) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZYME Stock Alerts